{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039356","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.072089+00:00","generated_at":"2026-06-12T02:23:33.786457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Beam Q2 net loss $82.8M; BEAM-101/201 trials advance, in vivo programs accelerated","bullets":["Q2 net loss $82.8M ($1.08/shr) vs $72.0M ($1.02/shr) in Q2 2022; R&D spend $97.6M (up 31% YoY).","Cash $1.1B unchanged from year-end 2022; runway extends at least into 2025.","BEACON trial: consented patients sufficient to fill sentinel and initiate expansion; initial data expected 2024.","BEAM-201: first patient consented, dosing expected Q3 2023; multiple clinical sites open.","BEAM-302 accelerated to first in vivo liver regulatory filing in Q1 2024; BEAM-301 filing in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039356","json":"https://secwatch.observer/filing/0000950170-23-039356.json","markdown":"https://secwatch.observer/filing/0000950170-23-039356.md","text":"https://secwatch.observer/filing/0000950170-23-039356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/0000950170-23-039356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/beam-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:23:33.786457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6226c51eb0c40bd5e07cf2883b6b6a992b8b575e","claim":"Beam Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/0000950170-23-039356-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}